VisionSys AI Says In Advanced Talks For $90M Investment At $1.50/Share To Fund BCI And AI Healthcare Expansion

VisionSys AI Inc. (NASDAQ:VSA) ("VSA" or the "Company") today announced that it is in advanced discussions with a strategic investor regarding a proposed strategic investment. Based on the terms currently under discussion, the investor plans to invest a total of $90 million in VSA at a price of $1.50 per share.

This proposed investment represents a key step forward for VSA in capital formation, strategic collaboration, and business transformation. The Company is currently focused on advancing its Brain-Computer Interface ("BCI") business by leveraging its core algorithms and related software and hardware systems, while accelerating the development of AI-powered healthcare and biotechnology solutions. The Company believes that this potential investment could provide meaningful support for its technology research and development, product commercialization, and global expansion, further strengthening its overall competitiveness in the frontier technology services sector and the global capital markets.

Use of Proceeds and Strategic Execution

The Company preliminarily plans to use the proceeds from the proposed investment in the following areas:

• to continue increasing investment in core BCI algorithms and system platforms, accelerating the transition of key technologies toward engineering development and scalable applications;
• to expedite the product development and commercial deployment of AI-powered healthcare and biotechnology solutions;
• to strengthen integrated software and hardware capabilities and enhance system stability, scalability, and operational efficiency;
• to support channel expansion and localized operations in key international markets and further improve the Company's global business footprint; and
• to supplement working capital and optimize the Company's capital structure in support of its long-term, sustainable growth.

If successfully completed, the proposed investment is expected to improve the Company's liquidity position and financial flexibility, providing stronger capital support for the advancement of its key businesses and strategic initiatives.

Focusing on the Core BCI Opportunity

The Company views the BCI business as one of its core strategic priorities for future growth. BCI technology is designed to establish a direct communication pathway between the human brain and external devices, with clear commercialization potential in healthcare applications, including motor function restoration, neurological disease treatment, speech recovery, and sensory rehabilitation.

In the near term, the Company intends to prioritize non-invasive BCI products in order to achieve faster commercialization and market validation, with an initial focus on consumer healthcare and wellness management. Target product categories include intelligent bionic hands, EEG-based sleep assistance devices, attention training headbands, and meditation devices.

Over the medium to long term, the Company plans to expand gradually into serious medical applications, focusing on functional restoration and neuromodulation solutions for major conditions such as paralysis, Parkinson's disease, and blindness. If these technologies achieve key breakthroughs and obtain regulatory approval, they could establish significant technological barriers and substantial commercial value. The Company also intends to explore the broader application of BCI technology in consumer-oriented scenarios such as education, intelligent interaction, gaming and entertainment, and smart home control, thereby expanding its long-term market opportunity.